Disease-Free Survival [přežití bez známek nemoci]

topical
1 449
Terms

přežití po terapii bez příznaků nemoci

 

Survival, Disease-Free

Persistent link   https://www.medvik.cz/link/D018572
Definition

Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.

Annotation
usually NIM; coordinate with specific disease /ther or more specific qualifier
obvykle NIM; kombinuj s konkrétní nemocí s podheslem /terapie nebo přesnějšími kvalifikátory
DUI
D018572 MeSH Browser
CUI
M0027839
Previous indexing
Prognosis (1980-1994)
History note
95
Public note
95

E Analytical, Diagnostic and Therapeutic Techniques and Equipment
E01 Diagnosis 1 793
E01.789 Prognosis 9 717
E01.789.800 Treatment Outcome 21 809
E01.789.800.190 Disease-Free Survival 1 449
E01.789.800.238 Early Termination of Clinical Trials 16
E01.789.800.262 Pathologic Complete Response 7
E01.789.800.285 Progression-Free Survival 520
E01.789.800.379 Response Evaluation Criteria in Solid Tumors 42
E01.789.800.570 Sustained Virologic Response 20
E01.789.800.665 Therapeutic Index 6
E01.789.800.713 Treatment Expectations
E01.789.800.760 Treatment Failure 686
E05 Investigative Techniques 209
E05.318 Epidemiologic Methods 1 030
E05.318.740 Statistics as Topic 13 095
E05.318.740.998 Survival Analysis 3 079
E05.318.740.998.300 Disease-Free Survival 1 449
E05.318.740.998.650 Kaplan-Meier Estimate 734
E05.318.740.998.738 Progression-Free Survival 520
E05.318.740.998.825 Proportional Hazards Models 476

N Health Care
N04 Health Services Administration 1 746
N04.761 Quality of Health Care 2 496
N04.761.559 Outcome and Process Assessment, Health Care 1 870
N04.761.559.590 Outcome Assessment, Health Care 587
N04.761.559.590.800 Treatment Outcome 21 809
N04.761.559.590.800.190 Disease-Free Survival 1 449
N04.761.559.590.800.379 Early Termination of Clinical Trials 16
N04.761.559.590.800.427 Pathologic Complete Response 7
N04.761.559.590.800.474 Progression-Free Survival 520
N04.761.559.590.800.569 Response Evaluation Criteria in Solid Tumors 42
N04.761.559.590.800.665 Sustained Virologic Response 20
N04.761.559.590.800.713 Therapeutic Index 6
N04.761.559.590.800.737 Treatment Expectations
N04.761.559.590.800.760 Treatment Failure 686
N05 Health Care Quality, Access, and Evaluation 687
N05.715 Quality of Health Care 2 496
N05.715.360 Health Care Evaluation Mechanisms 202
N05.715.360.575 Outcome and Process Assessment, Health Care 1 870
N05.715.360.575.575 Outcome Assessment, Health Care 587
N05.715.360.575.575.800 Treatment Outcome 21 809
N05.715.360.575.575.800.190 Disease-Free Survival 1 449
N05.715.360.575.575.800.379 Early Termination of Clinical Trials 16
N05.715.360.575.575.800.427 Pathologic Complete Response 7
N05.715.360.575.575.800.474 Progression-Free Survival 520
N05.715.360.575.575.800.569 Response Evaluation Criteria in Solid Tumors 42
N05.715.360.575.575.800.665 Sustained Virologic Response 20
N05.715.360.575.575.800.713 Therapeutic Index 6
N05.715.360.575.575.800.737 Treatment Effect Heterogeneity
N05.715.360.575.575.800.749 Treatment Expectations
N05.715.360.575.575.800.760 Treatment Failure 686
N05.715.360.750 Statistics as Topic 13 095
N05.715.360.750.795 Survival Analysis 3 079
N05.715.360.750.795.300 Disease-Free Survival 1 449
N05.715.360.750.795.650 Kaplan-Meier Estimate 734
N05.715.360.750.795.738 Progression-Free Survival 520
N05.715.360.750.795.825 Proportional Hazards Models 476
N06 Environment and Public Health 203
N06.850 Public Health 4 047
N06.850.520 Epidemiologic Methods 1 030
N06.850.520.830 Statistics as Topic 13 095
N06.850.520.830.998 Survival Analysis 3 079
N06.850.520.830.998.300 Disease-Free Survival 1 449
N06.850.520.830.998.650 Kaplan-Meier Estimate 734
N06.850.520.830.998.825 Progression-Free Survival 520
N06.850.520.830.998.912 Proportional Hazards Models 476

Back Add